Clinical Trials

1,050 enrolled

Estrogen Receptor-Positive, HER2-Negative Advanced Breast Cancer

NCT05735080 2026-04-01

INX-315-01

150 enrolled

BreastGynecologic

Breast Neoplasms, Neoplasm Metastasis, Ovarian Neoplasms

NCT06830720 2026-04-01

CAROLEEN

Recruiting

3,250 enrolled

Breast Neoplasms

NCT04791384 2026-03-31

Phase Ib/II Trial of Abemaciclib and Elacestrant in Patients With Brain Metastasis Due to HR+/Her2- Breast Cancer

Phase 1/2 Terminated

5 enrolled

Breast Neoplasms

NCT05307705 2026-03-27

PIKASSO-01

193 enrolled

Phase 3 Not yet recruiting

Breast Neoplasms

NCT05999994 2026-03-27

CAMPFIRE

Phase 2 Recruiting

105 enrolled

Tumor-Agnostic

Neoplasms

NCT07492641 2026-03-25

BGB-43395 Plus Letrozole Versus CDK4/6i Plus Letrozole for Patients With Advanced or Metastatic HR+/HER2- Breast Cancer Who Have Not Received Prior Treatment for Advanced or Metastatic Disease

1,056 enrolled

Phase 2 Active not recruiting

HR+/HER2- Breast Cancer

NCT06413706 2026-03-24

A Study Comparing Abemaciclib Plus Temozolomide to Temozolomide Monotherapy in Children and Young Adults With High-grade Glioma Following Radiotherapy

45 enrolled

CNS

Brain Neoplasms, Glioma, Neoplasms, Spinal Cord Neoplasms

NCT05573126 2026-03-20

Phase 1/2 Study to Evaluate EP0062 as Monotherapy and in Combination in Patients With Advanced or Metastatic AR+/HER-2-/ER+ Breast Cancer

95 enrolled

Breast Neoplasms

NCT07174336 2026-03-20

A Study of Tersolisib (LY4064809/STX-478) With Other Anti-Cancer Treatments in Participants With Advanced Breast Cancer With a Genetic Change (PIK3CA)

920 enrolled

Breast Neoplasms, Neoplasm Metastasis

NCT03424005 2026-03-16

Morpheus-panBC

792 enrolled

Breast Neoplasms

NCT04862663 2026-03-12

CAPItello-292

895 enrolled

Locally Advanced (Inoperable) or Metastatic Breast Cancer

NCT07100106 2026-03-12

A Study to Evaluate the Effect of GDC-4198 Alone and in Combination With Giredestrant Versus Abemaciclib and Giredestrant in Participants With Locally Advanced or Metastatic Estrogen Receptor-Positive (ER+), Human Epidermal Growth Factor Receptor-Negative (HER2-) Breast Cancer

285 enrolled

Phase 2 Active not recruiting

Breast Neoplasms

NCT04931342 2026-03-10

BOUQUET

176 enrolled

Gynecologic

Ovarian Neoplasms

NCT05999968 2026-03-05

Abemaciclib Plus Darolutamide in Prostate Cancer That Has Spread After Initial Treatment

Phase 1 Completed

10 enrolled

Genitourinary

Prostatic Neoplasms

NCT04238819 2026-03-02

A Study of Abemaciclib (LY2835219) in Combination With Other Anti-Cancer Treatments in Children and Young Adult Participants With Solid Tumors, Including Neuroblastoma

Phase 1/2 Completed

47 enrolled 36 charts

CNSSarcoma

Diffuse Intrinsic Pontine Glioma, Brain Neoplasms, Ependymoma, Glioblastoma, Glioma, Medulloblastoma, Neuroblastoma, Rhabdomyosarcoma, Sarcoma, Ewing, Osteosarcoma, Rhabdoid Tumor

NCT06760637 2026-03-02

FourLight-3

1,020 enrolled

Phase 1/2 Active not recruiting

Unilateral Breast Neoplasms, Breast Neoplasms, Recurrence

NCT05548127 2026-02-10

TACTIVE-U: A Study to Learn About the Study Medicine (Vepdegestrant) When Given With Other Medicines in People With Advanced or Metastatic Breast Cancer (Sub-Study A)

37 enrolled

Phase 3 Active not recruiting

Breast Neoplasms

NCT02152631 2026-02-06

JUNIPER

453 enrolled 18 charts

Thoracic

Carcinoma, Non-Small-Cell Lung

NCT02747004 2026-02-06

Next MONARCH 1

Phase 2 Active not recruiting

234 enrolled 20 charts

Phase 3 Active not recruiting

Breast Neoplasms

NCT02763566 2026-02-05

MONARCH plus

463 enrolled 20 charts

Phase 3 Active not recruiting

Breast Neoplasms

NCT02246621 2026-02-03

MONARCH 3

493 enrolled 23 charts 1 FDA

Breast Neoplasms

NCT03616587 2026-01-28

SERENA-1

396 enrolled

Breast Neoplasms

NCT02057133 2026-01-26

A Study of LY2835219 (Abemaciclib) in Combination With Therapies for Breast Cancer That Has Spread

198 enrolled

Breast Neoplasms

NCT02779751 2026-01-26

A Study of Abemaciclib (LY2835219) in Participants With Non-Small Cell Lung Cancer or Breast Cancer